For prescribing information, click here

This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777.

Resources

Cervical Dystonia

Cervical Dystonia - Resources
Cervical Dystonia - Resources

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) therapeutic indications

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) is indicated in adults for symptomatic treatment of spasmodic torticollis

Please click here to see the full therapeutic indications.

Product Resources

Injection Handbook – Cervical Dystonia
Injection Handbook – Cervical Dystonia
PDF / PowerPoint Deck 19 pages

A reference guide to the administration of Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) for the treatment of cervical dystonia in adults, including the identification of muscles using ultrasound, and the recommended injection technique per muscle.

DYS-UK-009019 | November 2024
Dose Map for Cervical Dystonia
Dose Map for Cervical Dystonia
PDF / PowerPoint Deck 3 pages

A downloadable reference guide to the dosing of Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) for the symptomatic treatment of cervical dystonia in adults.

DYS-UK-008957 | November 2024
Dilution Guide
Dilution Guide
PDF / PowerPoint Deck 2 pages

A reference guide to reconstituting and diluting Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex).

DYS-UK-009018 | November 2024
Reconstitution Guide
Reconstitution Guide
Video 10:03

How to prepare, reconstitute and store Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex).

DYS-UK-009047 | November 2024
Mechanism of Action of Botulinum Neurotoxin Type A
Mechanism of Action of Botulinum Neurotoxin Type A
Video 3:13

Short animation explaining the mechanism of action of botulinum neurotoxin type A

DYS-UK-009022 | November 2024

eLearning

Cervical Dystonia Disease Background – eLearning Module
Cervical Dystonia Disease Background – eLearning Module
PDF / PowerPoint Deck 26 pages

An overview of clinical characteristics of cervical dystonia, the sub-types of CD, and the impact CD can have on patients.

DYS-UK-009105 | November 2024
Cervical Dystonia Diagnosis – eLearning Module
Cervical Dystonia Diagnosis – eLearning Module
PDF / PowerPoint Deck 22 pages

An overview of the clinical history of CD in adults, the methods of diagnosing cervical dystonia, and the clinical examination required for patients suspected of having CD.

DYS-UK-009015 | November 2024
Clinical Studies for Dysport<sup>®</sup> (Clostridium botulinum type A toxin-haemagglutinin complex)
Clinical Studies for Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex)
PDF / PowerPoint Deck 20 pages

An overview of the phase 3 clinical studies of Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) in cervical dystonia.

DYS-UK-009052 | November 2024
Clinical Case Study: 36-year-old female with Cervical Dystonia
Clinical Case Study: 36-year-old female with Cervical Dystonia
Video 05:41

Presented by: Dr Tim Harrower.

DYS-UK-008955 | November 2024
Patient case study – 51-year-old female with CD
Patient case study – 51-year-old female with CD
Video 14:04

Includes footage of the clinical assessment and injection procedure. Presented by: Dr Anna Castagna.

DYS-UK-008956 | November 2024
Patient case study – 60-year-old female with CD
Patient case study – 60-year-old female with CD
Video 13:10

Includes footage of the clinical assessment and injection procedure. Presented by: Dr Anna Castagna.

DYS-UK-009279 | November 2024
Advanced concepts in diagnosis and therapy of cervical dystonia: The Col-Cap-Concept
Advanced concepts in diagnosis and therapy of cervical dystonia: The Col-Cap-Concept
Video 33:46

Presented by: Prof W. Jost.

DYS-UK-008959 | November 2024
How Do I Approach Botulinum Neurotoxin (BoNT) failures?
How Do I Approach Botulinum Neurotoxin (BoNT) failures?
Video 14:04

Presented by: Dr Alfonso Fasano, MD, PhD

DYS-UK-008962 | November 2024
Life between Botulinum Neurotoxin Type A (BoNT-A) injections: The gap for patients living with Cervical Dystonia
Life between Botulinum Neurotoxin Type A (BoNT-A) injections: The gap for patients living with Cervical Dystonia
Video 34:04

Presented by: Dr Timothy Harrower.

DYS-UK-008958 | November 2024

Talking Head Videos

A practical guide to implementing a flexible PIFU model
A practical guide to implementing a flexible PIFU model
Video 23:54

How the implementation of a Patient-Initiatied Follow-Up (PIFU) model may be a practical solution to capacity challenges and help achieve efficiency savings within BoNT-A services.

DYS-UK-008949 | November 2024
Making sense of the changing NHS and funding flows
Making sense of the changing NHS and funding flows
Video 12:15

Judy Willits discusses how the NHS payment scheme has evolved and what the changes could mean for your botulinum toxin services.

DYS-UK-008947 | November 2024
Demystifying the Clinical Relevance of BoNT Immunogenicity
Demystifying the Clinical Relevance of BoNT Immunogenicity
Video 06:00

Learn about the difference between neutralising and non-neutralising antibodies, and factors to consider when investigating non-response to BoNT treatment. Presented by: Dr Tim Harrower.

DYS-UK-009026 | November 2024

Contact your Ipsen representative

Send request
Resources